810 results about "Hemostatics" patented technology

The present disclosure relates to hemostatic implants including a porous substrate having a first hydrogel precursor and a second hydrogel precursor applied thereto in a manner such that the first hydrogel precursor and second hydrogel precursor do not react with each other until the implant is placed at the site of implantation and exposed to the physiological fluids of a patient.

An apparatus for applying clips to tissue, comprises a plurality of clips, each of the clips including a proximal end having a pair of opposed jaws and a distal end including a linking feature, where the clips are linked to one another to form a clip chain with a linking feature of a distal-most one of the clips being gripped between the jaws of an immediately proximal one of the clips and a control linkage coupled to a proximal-most one of the clips for applying tension and compression to the clip chain in combination with a magazine containing the clip chain, the magazine including an abutment surface sized to prevent passage distally therebeyond of a clip having received between its jaws a linking feature of an immediately distal clip and an opening location within which the jaws of a clip are permitted to open to release a linking feature therefrom.

The present invention relates to a haemostatic multilayer bandage that comprises preferably a thrombin layer between two fibrinogen layers. The dressing may contain other resorbable materials such as glycolic acid or lactic acid based polymers or copolymers. The inventive haemostatic bandage is useful for the treatment of wounded tissue.

The present invention is directed to a hemostatic textile, comprising: a material comprising a combination of glass fibers and one or more secondary fibers selected from the group consisting of silk fibers; ceramic fibers; raw or regenerated bamboo fibers; cotton fibers; rayon fibers; linen fibers; ramie fibers; jute fibers; sisal fibers; flax fibers; soybean fibers; corn fibers; hemp fibers; lyocel fibers; wool; lactide and/or glycolide polymers; lactide/glycolide copolymers; silicate fibers; polyamide fibers; feldspar fibers; zeolite fibers, zeolite-containing fibers, acetate fibers; and combinations thereof; the hemostatic textile capable of activating hemostatic systems in the body when applied to a wound. Additional cofactors such as thrombin and hemostatic agents such as RL platelets, RL blood cells; fibrin, fibrinogen, and combinations thereof may also be incorporated into the textile. The invention is also directed to methods of producing the textile, and methods of using the textile to stop bleeding.

The present invention is directed to a hemostatic wound dressing that utilizes a fibrous, fabric substrate made from carboxylic-oxidized cellulose and containing a first surface and a second surface opposing the first surface, the fabric having flexibility, strength and porosity effective for use as a hemostat; and further having a porous, polymeric matrix substantially homogeneously distributed on the first and second surfaces and through the fabric, the porous, polymeric matrix being made of a biocompatible, water-soluble or water-swellable cellulose polymer, wherein prior to distribution of the polymeric matrix on and through the fabric, the fabric contains about 3 percent by weight or more of water-soluble oligosaccharides.

The present invention is directed to a woven fabric having the modified crowsfoot weave pattern shown in FIGS. 2A and 2B. The present invention is directed to a woven fabric comprising about 65 wt % fiberglass yarn and about 35 wt % bamboo yarn, the woven fabric (1) being about 15.0 ounces per square yard (OSY); (2) having a thread count of about 760; and (3) having the modified crowsfoot weave pattern shown in FIGS. 2A and 2B. Additional ingredients may also be added to the woven fabrics of the invention to enhance the hemostatic properties.

The invention relates to a modified starch material for biocompatible hemostasis, biocompatible anti-adhesion, tissue healing promotion, absorbable surgery sealing and tissue adhesion. The invention applies biocompatible modified starch to animal tissues, wherein the modified starch material has the molecular weight of more than 15,000 daltons, and the particle diameter of between 1 and 1,000 mu m. The modified starch hemostatic material has stypticity, reduces hemorrhage, blood oozing and tissue fluid oozing of wounds, maintains relative moistening or drying of wound surfaces or the wounds, inhibits bacterium growth and inflammation reaction, and contributes to locally diminish inflammation of the wounds and relieve pain of patients. Moreover, the modified starch material can wash local parts after operation is over and remove redundant modified starch which does not participate in hemostasis, and can easily remove haemostatic under the condition of debridement treatment after self-help and first-aid treatment of war wounds; and hemostatic materials with a small amount of modified starch can be absorbed by the body, so that the pain of tearing of gauzes and bandages on people is avoided.

The present invention provides a hemostatic porous sponge comprising a matrix of a fibrous biomaterial and particles of a fluid absorbing, particulate material adhered to said matrix material, a method of producing these sponges and their use for wound healing.

A method of treating peripheral bronchopleural fistula using a collagen matrix hemostatic pad. The method includes the following steps: (1) selecting a peripheral bronchopleural fistula; (2) selecting a collagen matrix hemostatic pad having sufficient size to cover the fistula; (3) aligning the collagen matrix hemostatic pad completely over the fistula; and (4) securing the collagen matrix hemostatic pad to the tissue sorrounding the fistula.

Medical device used to cause hemostasis of blood vessels using a clip arrangement delivered to a target region through an endoscope. Method for using the device to cause hemostasis of a blood vessel through an endoscope. Medical device including a reversibly closeable clip, a locking arrangement, a control wire, a sheath, and a handle with an actuating trigger. Through the endoscope, hemostatic clipping device that is fully reversible and lockable. Hemostatic clip that reversibly targets and clips bleeding ulcers.

A hemostatic compression bandage includes a flexible backing element, a powdered hemostatic substance, and a flexible film element. The backing element includes a first containment region. The film element includes a second containment region corresponding to the first containment region. The film element is removably attached to the backing element so as to contain the hemostatic substance between the backing element and the film element within a volume defined by the first containment region and the second containment region. The backing element includes a pressure region located outside of the first containment region. The film element includes a pull-tab region located outside of the second containment region and at a first side of the bandage. The pull-tab region has sufficient length to be folded back across the second containment region and extending beyond a second side of the bandage that is opposite the first side of the bandage.

The invention relates to a biocolloid hemostatic prepared by aldehyde-modified sodium alginate and amine-modified gelatine. Sodium alginate and gelatine as raw materials; according to ratio, aldehyde-modified sodium alginate solution with the concentration of 5-25% and the same volume of amine-modified gelatine solution with the concentration of 5-40% are mixed; sodium alginate is modified by aldehyde through sodium periodate oxidation; and then gel is obtained by mixing with gelatine modified by ethanediamine. The adopted gelatine and sodium alginate are safe and stable, have good biocompatibility and can be absorbed and degraded by organism. Gel is rapidly formed through Schiff base reaction of aldehyde-modified sodium alginate and amine-modified gelatine, and the gel has the same gel-forming time as fibrin glue but better adhesion property and adhesion strength, can be acted on any part of body through simple local spraying or injection, and can be used as substitute product of fibrin glue.

Provided are a hemostatic clip and a hemostatic clip operation apparatus using the same that can rapidly stop bleeding from a bleeding area of a blood vessel when a middle or large diameter blood vessel partially bleeds during an abdominal operation or a surgery using an endoscope. The hemostatic clip operation apparatus includes a handle, a first gripper configured to primarily stop bleeding from a bleeding area of a blood vessel, a second gripper configured to receive the first gripper and symmetrically bend a closed-loop shaped-hemostatic clip to secondarily clip a periphery of the bleeding area stopped by the first gripper, and a gripper driver configured to connect the handle to the first and second grippers to be interlocked with operation of the handle to operate sequential stopping of bleeding and clipping of the first and second grippers.

The invention relates to a medical wound surface hemostatic and wound healing agent, which is characterized in that the invention consists of two parts of water solution, one part is the oxidative polysaccharide water solution containing dialdehyde, and the other part is the water-soluable chitosan water solution. The medical wound surface hemostatic and wound healing agent can be applied in the preparation of drugs or medical devices for wound surface sealing and wound surface hemostasis, and the invention can also be applied in the preparation of drugs or medical devices for the promotion of wound surface healing and the prevention of postoperative tissue adhesion. The medical wound surface hemostatic and wound healing agent of the invention has significant effects on wound surface sealing, hemostasis, promotion of wound surface healing, prevention of postoperative tissue adhesion and other aspects, at the same time, the biocompatibility is good, which can not cause the tissue immune response, and the polysaccharides can not generate side effects on organisms after the in vivo degradation, so the safety is good.

The present invention relates generally to medical devices for applying hemostatic composition to a puncture or wound site with indwelling tubular element, such as catheter, introducer or tube therein, particularly a hemostatic pad with an opening therethrough in order to allow egress of the indwelling tubular element through the hemostatic pad as the hemostatic pad provide hemostasis at the hemorrhaging site. The device may be applied to, or removed from, the wound site while the tubular element is in place. A method for effecting hemostasis at a puncture wound, includes applying pressure proximal to the puncture wound, and directing a cationic biopolymer of glucosamine application surface of a closure pad against the puncture wound with force sufficient to prevent fluid from exiting the puncture wound. Then the pressure proximal to the puncture wound is removed and the force on the closure pad is maintained for at least a first predetermined time period. The force on the closure pad is removed if hemostasis is verified. The puncture wound may then be dressed over the closure pad, and the dressing and the closure pad removed after a second predetermined time period.

The present invention discloses a preparation method of an antiphlogistic and antisticking stanching sponge. The preparation method includes the following steps: through the cross linking of polyvinyl alcohol, chitosan gel microspheres are fixed on the inner wall of a sponge, the sponge is then soaked in antiphlogistic solution and antisticking solution, and finally, the PVA/drug-loaded chitosan antiphlogistic and antisticking stanching sponge is prepared. The antiphlogistic and antisticking stanching sponge prepared by the method can be trimmed according to the size of an operative cavity in order to be placed into the corresponding part, the pressure on the circumference is uniform, blood can be thoroughly stanched, and the injury on the mucous membrane of the operative cavity is little. The antiphlogistic and antisticking stanching sponge prepared by the method, which has good antiphlogistic, stanching and antisticking functions, biocompatibility, and mechanical and anti-oedema properties, can promote the injured tissues to have strong recovering capability, prevent rebleeding and avoid the inevitable potential virus hazard caused by glutin and animal collagen proteins, so the use safety is greatly improved, and moreover, the antiphlogistic and antisticking stanching sponge can alleviate the pain and discomfort suffered by patients. The antiphlogistic and antisticking stanching sponge is expected to substitute the import products and have remarkable social and economic benefits.

The present invention relates generally to agents and devices for promoting hemostasis and tissue sealing and, more particularly, to hemostatic pads comprising bioabsorbable scaffolds that can deliver lyophilized hemostasis promoting proteins, such as fibrinogen and thrombin, to a wound site or injured organ or tissue.

The invention relates to a hemostatic clamp with a four-bar structure, which comprises a clamp head part, an outer tube part, an inhaul cable and a handle, wherein the inhaul cable is connected with the handle through a sliding ring, the outer pipe part is fixedly connected with the handle, the clamp head part consists of two clamp heads and two connecting poles, the clamp handle and the connecting pole of each clamp head form a four-bar structure, the two clamp heads are pin-jointed on a clamp head seat, the clamp head seat is connected with the outer tube part, and the two connecting poles are pin-jointed on a pull rod arranged on the front end of the inhaul cable. According to the hemostatic clamp, the sliding ring slides on the handle to pull the inhaul cable to move front and back; and the pull rod drives the four-bar structure to move, thus the clamp heads are closed and opened. The hemostatic clamp can be repeatedly flexibly opened and closed, and is most suitable for a treating device for hemostasis in body cavity.

The invention provides a hemostatic crosslinked composition. The hemostatic crosslinked composition is prepared from gelatin and acyl- or carboxyl-containing polysaccharide. The invention also provides a preparation method and use of the hemostatic crosslinked composition. The invention also provides a hemostatic antistick material containing the hemostatic crosslinked composition. The hemostatic crosslinked composition has the characteristics of a hemostatic gelatin product and a hemostatic polysaccharide product. Compared with the existing hemostatic products, the hemostatic crosslinked composition obviously improves absorption properties, haemostasis and blood clotting performances and degradability. The hemostatic antistick material provided by the invention has the advantages of high haemostasis efficiency and controllable internal-degradation time, can satisfy requirements on hemostatic materials and especially on medical hemostatic antistick materials, and has a wide market application prospect.